Quick Answer
Axsome Therapeutics, Inc. reported Net Income Loss of -$183.17 million for the year ending 2025.
- Axsome Therapeutics, Inc. showed an increase of +36.2% in Net Income Loss from 2024 to 2025.
- This data is from Axsome Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Axsome Therapeutics, Inc.'s Net Income Loss has declined by 2,952.6%.
- Historical annual values: Fiscal year 2025: -$183.17 million | Fiscal year 2024: -$287.22 million | Fiscal year 2023: -$239.24 million | Fiscal year 2022: -$187.13 million | Fiscal year 2021: -$130.40 million | Fiscal year 2020: -$102.90 million | Fiscal year 2019: -$68.35 million | Fiscal year 2018: -$30.97 million | Fiscal year 2017: -$28.94 million | Fiscal year 2016: -$27.20 million | Fiscal year 2015: -$12.21 million | Fiscal year 2014: -$6.00 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: